109 related articles for article (PubMed ID: 12097998)
1. Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia.
Gora-Tybor J; Blonski JZ; Robak T
Neoplasma; 2002; 49(3):145-8. PubMed ID: 12097998
[TBL] [Abstract][Full Text] [Related]
2. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
Gora-Tybor J; Blonski JZ; Robak T
Mediators Inflamm; 2003 Jun; 12(3):167-71. PubMed ID: 12857600
[TBL] [Abstract][Full Text] [Related]
3. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
4. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
8. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
Krykowski E; Warzocha K; Robak T
Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
[TBL] [Abstract][Full Text] [Related]
9. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
10. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
11. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
12. Circulating endothelial cells in patients with chronic lymphocytic leukemia.
Go RS; Jobe DA; Asp KE; Callister SM; Mathiason MA; Meyer LA; Bottner WA; Cole CE; Farnen JP; Frisby KA
Ann Hematol; 2008 May; 87(5):369-73. PubMed ID: 18193423
[TBL] [Abstract][Full Text] [Related]
13. Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.
Molica S; Digiesi G; Mauro F; Mirabelli R; Cutrona G; Vitelli G; Morabito F; Iuliano F; Foà R; Ferrarini M
Leuk Res; 2009 Jan; 33(1):162-5. PubMed ID: 18556064
[TBL] [Abstract][Full Text] [Related]
14. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy.
Andrys C; Borska L; Pohl D; Fiala Z; Hamakova K; Krejsek J
Arch Dermatol Res; 2007 Mar; 298(10):479-83. PubMed ID: 17221216
[TBL] [Abstract][Full Text] [Related]
15. 2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo.
Rogalińska M; Błoński JZ; Hanausek M; Walaszek Z; Robak T; Kiliańska ZM
Cancer Detect Prev; 2004; 28(6):433-42. PubMed ID: 15582267
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
Wróbel T; Poreba M; Mazur G; Poreba R; Pyszel A; Beck B; Steinmetz-Beck A; Andrzejak R; Kuliczkowski K
Neoplasma; 2006; 53(3):253-8. PubMed ID: 16652197
[TBL] [Abstract][Full Text] [Related]
17. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
18. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
19. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
[TBL] [Abstract][Full Text] [Related]
20. 2-chlorodeoxyadenosine (cladribine) induced allergic cutaneous reactions with eosinophilia in a patient with B-cell chronic lymphocytic leukemia.
Robak T; Sysa-Jedrzejowska A; Robak E; Dabkowski J; Blasinska-Morawiec M
J Med; 1997; 28(3-4):199-209. PubMed ID: 9355024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]